Randomized controlled trials (RCTs) are the foundation of evidence-based medicine and help to influence medical practise. Compromises in data integrity in RCTs weaken the legitimacy of this essential scientific instrument and endangers patients. Although there have been a considerable number of retractions owing to data difficulties in obstetrics and gynaecology in recent years, many problematic RCTs may still go unnoticed since there is a widespread lack of readiness to anticipate and tackle research misconduct. In this post, the study will highlight the importance of analysing research misconduct, outline methods used to discover prior occurrences of misconduct, and offer viable remedies. There is no established process in place to monitor comments on published publications, and the existing approach for dealing with possible research misconduct is inadequate. Fortunately, there are techniques for assessing data integrity in RCTs that use both individual participant data and do not use individual participant data. Investigating scientific misconduct can be aided by reviewing all publications by a major author or author group to discover duplication and patterns of continuous wrongdoing. There is an urgent need to enhance the system for investigating data tampering. The process for dealing with misbehaviour should put patients and readers ahead of trial authors and their institutions.An equally pressing issue is the establishment of procedures to prevent tainted trials from contaminating evidence synthesis or misleading practise.
